Avalo Therapeutics, Inc.
AVTX
$9.88
$0.515.44%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 192.00K | 249.00K | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 192.00K | 249.00K | 0.00 |
| Cost of Revenue | 10.66M | 5.91M | 5.54M | 6.50M | 2.86M |
| Gross Profit | -10.66M | -5.91M | -5.35M | -6.25M | -2.86M |
| SG&A Expenses | 5.24M | 5.55M | 5.23M | 4.29M | 4.53M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.32M | 14.67M | 13.50M | 13.11M | 9.47M |
| Operating Income | -19.32M | -14.67M | -13.31M | -12.86M | -9.47M |
| Income Before Tax | -20.75M | -13.14M | -35.23M | 23.02M | 98.47M |
| Income Tax Expenses | 16.00K | 8.00K | 114.00K | -14.00K | 7.00K |
| Earnings from Continuing Operations | -20.77M | -13.15M | -35.34M | 23.04M | 98.46M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.77M | -13.15M | -35.34M | 23.04M | 98.46M |
| EBIT | -19.32M | -14.67M | -13.31M | -12.86M | -9.47M |
| EBITDA | -19.18M | -14.53M | -13.24M | -12.83M | -9.44M |
| EPS Basic | -1.92 | -1.25 | -3.44 | 0.98 | 4.21 |
| Normalized Basic EPS | -1.20 | -0.78 | -2.15 | 2.59 | 59.57 |
| EPS Diluted | -1.92 | -1.25 | -3.44 | -2.83 | -14.07 |
| Normalized Diluted EPS | -1.20 | -0.78 | -2.15 | 1.33 | 8.05 |
| Average Basic Shares Outstanding | 10.83M | 10.51M | 10.23M | 5.55M | 1.03M |
| Average Diluted Shares Outstanding | 10.83M | 10.51M | 10.23M | 10.78M | 7.65M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |